. Author manuscript; available in PMC: 2013 Sep 18.

Published in final edited form as: Biomed Pharmacother. 2010 Nov 4;64(10):723–732. doi: 10.1016/j.biopha.2010.10.001

Table 2.

Therapeutic indices calculated for variant PBGs.

Compound	Linkers	Methylenes per repeat	Therapeutic index
Compound	Linkers	Methylenes per repeat	VII-IIIB^a,^b	VII-BaL^a	CFI-IIIB^c	CAI-IIIB^c
PEB	2-2	4	14	ND	ND	ND
PEHMB	2-6	8	78	53	14	86
PTMB	4-4	8	17	ND	ND	ND
PPHMB	3-6	9	72	1	3	77
PBHMB	4-6	10	31	17	6	50
PEOMB	2-8	10	62	52	5	59
PHMB	6-6	12	10	ND	ND	ND
PEHMB^d	2-6	8	7000	266	ND	ND

ND: not determined.

An in vitro TI was calculated for each compound by dividing its CC₅₀ value (2-h exposure) by the IC₅₀ value determined in the VII-IIIB or VII-BaL assay.

In vitro TIs for PEB, PTMB, and PHMB were calculated using data from previous studies [16].

An in vitro TI was calculated for each compound by dividing its CC₅₀ value (10-min exposure) by the IC₅₀ value determined in the CFI-IIIB or CAI-IIIB assay.

PEHMB (2-6) (also known as NB325) produced using an improved synthesis protocol and partial purification.